Core Viewpoint - China Health Group (00673.HK) expects to report a net loss attributable to shareholders of approximately HKD 66 million to HKD 70 million for the fiscal year 2025, compared to a net loss of approximately HKD 40.2 million for the fiscal year 2024 [1] Group 1 - The increase in losses for the fiscal year 2025 is primarily due to several factors, including a provision for litigation expenses of USD 4 million related to a judgment from the appellate court regarding a claim by Capital Foresight Limited [2] - Other income from the "other payables reversal" account is expected to decrease from approximately HKD 31.2 million in fiscal year 2024 to about HKD 16.3 million in fiscal year 2025, due to the reversal of payables after the High Court's dismissal of the claim [2] - The gross profit for fiscal year 2025 is projected to decrease by approximately HKD 4.4 million to about HKD 9.2 million, compared to approximately HKD 13.6 million in fiscal year 2024 [2] Group 2 - The negative factors affecting the fiscal year 2025 results are partially offset by a reduction in sales, distribution, and administrative expenses, which are expected to decrease by approximately HKD 14.7 million to about HKD 37 million, compared to approximately HKD 51.7 million in fiscal year 2024 [2]
中国卫生集团(00673.HK)预期2025财年亏损增加